Tango Therapeutics, Inc. (TNGX)
$22.19-0.14%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.8B
- Beta
- 1.17
- P/E (TTM)
- -26.11
- Short % float
- 54.26%
- Days to cover
- 12.5
- SI change
- +6.3%
- 1W
- +1.65%
- 1M
- -7.12%
- vs SPY 1W
- +2.63%
- vs SPY 1M
- -8.98%
Industry peers
FMP comparable companies · ranked by market cap
- RVMDSELLRevolution Medicines, Inc.$40.3BRECOVERYQ 30$189.76+2.70%
- ERASSELLErasca, Inc.$5.6BRECOVERYQ 3$16.03-0.54%
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 2$17.88-1.73%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 24$36.11-1.17%
- NRIXSELLNurix Therapeutics, Inc.$2.3BBEARQ 12$22.35+6.96%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$5.00-0.85%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on TNGX?
- LOPJLB’s latest quantitative signal on Tango Therapeutics, Inc. (TNGX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is TNGX in?
- Tango Therapeutics, Inc. (TNGX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Tango Therapeutics, Inc. (TNGX) do?
- Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphoryla…